Michael Cuttica

Michael Cuttica

Auto-generated profile, based on publicly available information

Michael Cuttica

Division of Pulmonary and Critical Care Northwestern University Feinberg School of Medicine Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
ALAdam Yuh Lin
Adam Yuh Lin
MCMichael J. Cuttica
Michael J. Cuttica
MIMichael G. Ison
Michael G. Ison
LGLeo Gordon
Leo Gordon
Ibrutinib, a known Burton's tyrosine kinase (BTK) and interleukin‐2 inducible T‐cell kinase (ITK) inhibitor, is used for the treatment of B‐cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic graft versus host disease following allogeneic hematopoietic cell transplantation. Because it is considered an immunosuppressant, continuation of ibrutinib is often debated when patients have an active infection, and this becomes an especially difficult decision in the setting of coronavirus disease 2019 (COVID‐19). Here, we describe a patient with CLL who was on ibrutinib then developed severe COVID‐19 infection requiring mechanical ventilation. We elected to continue ibrutinib the same day he was intubated, reasoning that BTK inhibition in myeloid immune cells has been shown to reduce or even reverse influenza‐mediated acute lung injury and that ITK inhibition in T cells has correlated with reduction in viral replication, and therefore may have an advantage in this setting. Ibrutinib also has been shown to block Src family kinases, which potentially could result in reduction of viral entry and the inflammatory cytokine response in the lungs. The patient was extubated after 9 days with a complex hospital course and eventually discharged on room air. The only way to rationally inform these decisions and explore similar potentially promising leads in this pandemic is to conduct carefully done clinical trials.

15 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
CPChiagozie Pickens
Chiagozie Pickens
CGCatherine A. Gao
Catherine A. Gao
MCMichael Cuttica
Michael Cuttica
SSSean B. Smith
Sean B. Smith
LPLorenzo Pesce
Lorenzo Pesce
RWRichard G. Wunderink
Richard G. Wunderink
Background: Severe community-acquired pneumonia secondary to SARS-CoV-2 is a leading cause of death. Current guidelines recommend patients with SARS-CoV-2 pneumonia receive empirical antibiotic therapy for suspected bacterial superinfection, but little evidence supports these recommendations. Methods: We obtained bronchoscopic bronchoalveolar lavage (BAL) samples from patients with SARS-CoV-2 pneumonia requiring mechanical ventilation. We analyzed BAL samples with multiplex PCR and quantitative culture to determine the prevalence of superinfecting pathogens at the time of intubation and identify episodes of ventilator-associated pneumonia (VAP) over the course of mechanical ventilation. We compared antibiotic use with guideline-recommended care. Results: The 179 ventilated patients with severe SARS-CoV-2 pneumonia discharged from our hospital by June 30, 2020 were analyzed. 162 (90.5%) patients had at least one BAL procedure; 133 (74.3%) within 48 hours after intubation and 112 (62.6%) had at least one subsequent BAL during their hospitalization. A superinfecting pathogen was identified within 48 hours of intubation in 28/133 (21%) patients, most commonly methicillin-sensitive Staphylococcus aureus or Streptococcus species (21/28, 75%). BAL-based treatment reduced antibiotic use compared with guideline-recommended care. 72 patients (44.4%) developed at least one VAP episode. Only 15/72 (20.8%) of initial VAPs were attributable to multidrug-resistant pathogens. The incidence rate of VAP was 45.2/1000 ventilator days. Conclusions: With use of sensitive diagnostic tools, bacterial superinfection at the time of intubation is infrequent in patients with severe SARS-CoV-2 pneumonia. Treatment based on current guidelines would result in substantial antibiotic overuse. The incidence rate of VAP in ventilated patients with SARS-CoV-2 pneumonia are higher than historically reported.

1 May 2012 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
AJAriel Jaitovich
Ariel Jaitovich
CHCarla Harmath
Carla Harmath
MCMichael Cuttica
Michael Cuttica

25 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
JAJason Arnold
Jason Arnold
CGCatherine A. Gao
Catherine A. Gao
EMElizabeth Malsin
Elizabeth Malsin
KTKristy Todd
Kristy Todd
AAA. Christine Argento
A. Christine Argento
SSSean B. Smith
Sean B. Smith
Background SARS-CoV-2 can cause severe respiratory failure leading to prolonged mechanical ventilation. Data are just emerging about the practice and outcomes of tracheostomy in these patients. We reviewed our experience with tracheostomies for SARS-CoV-2 at our tertiary-care, urban teaching hospital. Methods We reviewed the demographics, comorbidities, timing of mechanical ventilation, tracheostomy, and ICU and hospital lengths-of-stay (LOS) in SARS-CoV-2 patients who received tracheostomies. Early tracheostomy was considered <14 days of ventilation. Medians with interquartile ranges (IQR) were calculated and compared with Wilcoxon rank sum, Spearman correlation, Kruskal-Wallis, and regression modeling. Results From March 2020 to January 2021, our center had 370 patients intubated for SARS-CoV-2, and 59 (16%) had percutaneous bedside tracheostomy. Median time from intubation to tracheostomy was 19 (IQR 17 – 24) days. Demographics and comorbidities were similar between early and late tracheostomy, but early tracheostomy was associated with shorter ICU LOS and a trend towards shorter ventilation. To date, 34 (58%) of patients have been decannulated, 17 (29%) before hospital discharge; median time to decannulation was 24 (IQR 19-38) days. Decannulated patients were younger (56 vs 69 years), and in regression analysis, pneumothorax was associated was associated with lower decannulation rates (OR 0.05, 95CI 0.01 – 0.37). No providers developed symptoms or tested positive for SARS-CoV-2. Conclusions Tracheostomy is a safe and reasonable procedure for patients with prolonged SARS-CoV-2 respiratory failure. We feel that tracheostomy enhances care for SARS-CoV-2 since early tracheostomy appears associated with shorter duration of critical care, and decannulation rates appear high for survivors.

1 August 2017 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
JMJakob I. McSparron
Jakob I. McSparron
MHMargaret M. Hayes
Margaret M. Hayes
JPJason T. Poston
Jason T. Poston
LSLuke A. Seaburg
Luke A. Seaburg
AMAmy E. Morris
Amy E. Morris
ALAndrew M. Luks
Andrew M. Luks

28 January 2026 in Pulmonary Circulation
Verified
Journal Article
Open access
GCGiorgi Chilingarashvili
Giorgi Chilingarashvili
RMRuben Mylvaganam
Ruben Mylvaganam
RBRoberto J. Bernardo
Roberto J. Bernardo
ASAimal Shah
Aimal Shah
MCMichael Cuttica
Michael Cuttica
PRParth M. Rali
Parth M. Rali
Pulmonary Langerhans cell histiocytosis (PLCH) frequently complicated by pulmonary hypertension (PH), which markedly worsens prognosis. We retrospectively reviewed three institutional PLCH‐PH cases treated with off‐label Sotatercept added to background triple therapy and performed a systematic review of published PLCH‐PH reports (PubMed/Embase through May 2025). Our three patients (ages 69, 62, 49; all female) had progressive vascular disease despite optimized vasodilator therapy. Following Sotatercept, all experienced ≥ 3‐fold increases in 6‐min walk distance and improved functional class. Hemodynamics improved substantially: right‐atrial pressure −78.6%, pulmonary vascular resistance −75.5%, pulmonary artery systolic pressure −58.5%, mean PAP − 56.0%, PA diastolic pressure −51.0%, PAWP − 47.1%; cardiac output and index rose +75.9% and +73.8%, respectively. BNP/NT‐proBNP normalized. Systematic review identified 34 published cases (2010–2025): mean age 37.2 ± 13.7 years, 44.1% female, 45.7% current/former smokers. Reported management strategies included targeted vasodilators, cytotoxic PLCH therapies (e.g., cladribine), smoking cessation, and selective surgery/transplant. In this small series, Sotatercept added to background therapy produced marked clinical and hemodynamic gains in refractory PLCH‐PH. These effects of Sotatercept in Group 5 PH—are encouraging but limited by sample size and retrospective design. Prospective, collaborative studies are needed to define safety, efficacy, and optimal patient selection.